Jasper Therapeutics, Inc. Segments Disclosure
NOTE 15. SEGMENT INFORMATION
The Company has determined it operates as a operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. The Company’s chief operating decision maker, its (the “CEO”), manages the Company’s operations on a consolidated basis. The CEO assesses the segment’s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment’s personnel and general and overhead costs.
In addition to the significant expense categories included within net loss presented in the Company’s consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise total operating expenses:
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Personnel-related costs | $ | 27,497 | $ | 27,615 | ||||
| Facilities and overhead costs | 14,751 | 14,356 | ||||||
| Program costs | ||||||||
| Briquilimab platform | 6,727 | 5,637 | ||||||
| CMO | 12,912 | 9,500 | ||||||
| CSU | 12,047 | 10,689 | ||||||
| Asthma | 4,971 | 1,975 | ||||||
| CIndU | 3,294 | 2,234 | ||||||
| SCID | 1,466 | 2,409 | ||||||
| MDS/AML | 218 | 1,824 | ||||||
| Total program costs | 41,635 | 34,268 | ||||||
| Total operating expense | 83,883 | 76,239 | ||||||
| Other income, net | 8,082 | 4,970 | ||||||
| Net loss | $ | (75,801 | ) | $ | (71,269 | ) | ||
All long-lived assets are located in the United States.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Feb 28, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.